<DOC>
	<DOC>NCT00385840</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and the safety of a second vaccination with candidate vaccine compared to Fluarixâ„¢ administered intramuscularly in elderly aged 60 years and above</brief_summary>
	<brief_title>Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate</brief_title>
	<detailed_description>The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female age 60 years or older at the time of the revaccination, who previously participated in 107192 &amp; 107214 clinical trials. Subjects who the investigator believes can and will comply with the requirements of the protocol Written informed consent obtained from the subject. Free of an acute aggravation of the health status as established by clinical examination before entering into the study. Use of any investigational or nonregistered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs within 3 months prior to the first vaccine dose. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination. History of hypersensitivity to a previous dose of influenza vaccine. History of confirmed influenza infection within the last 12 months. History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) Acute disease at the time of enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>